Gilead Sciences Stock News

Biotech stocks operate under a core ethos. While there's been much talk about financially viable sectors – from tech to cryptocurrencies to even precious metals – when you think about it, nothing is more valuable than one's health.

Gilead stock reversed lower Monday after confirming it's testing a popular weight-loss mechanism as a treatment for a liver disease.

There are always opportunities in this market for stocks despite high total market valuation. Gilead Sciences offers strong growth potential with a well-covered dividend yield of 4.8% and a promising pipeline. Enbridge provides stable income with a 7.6% dividend yield, strong growth prospects, and trades below historical valuations.

Gilead stock jumped Friday after surprising Wall Street with preclinical test results for an under-the-radar weight-loss drug.

A success would be a gamechanger for the biotech company known for its HIV treatments.

SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced results from three new analyses for Yescarta® (axicabtagene ciloleucel) in relapsed/refractory (R/R) large B-cell lymphoma (LBCL), including both new clinical research and real-world evidence highlighting manufacturing and product characteristics of Yescarta, and outpatient administration of both Yesca...

Grant & Eisenhofer, Jenner Law, Burg Simpson, and The Lawrence Law Firm are jointly issuing the following public statement following Gilead's June 4th press release reported in the San Francisco Chronicle

Gilead Sciences, Inc. (NASDAQ:GILD ) Goldman Sachs 45th Annual Global Healthcare Conference June 12, 2024 1:20 PM ET Company Participants Daniel O'Day - Chairman and Chief Executive Officer Conference Call Participants Salveen Richter - Goldman Sachs Salveen Richter Good afternoon, everyone. Thank you so much for joining.